Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

NCT ID: NCT04739202

Last Updated: 2021-03-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-19
• Study Completion Date: 2023-10-26

Brief Summary

For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising platinum and fluoropyrimidine, the reported second line treatments are : 1) paclitaxel combined with ramucirumab (overall response rate (ORR) = 25%; median progression free survival (PFS) = 2.9 months; median overall survival (OS)= 5.9 months), or paclitaxel alone (ORR = 14%, median PFS = 2.9 months; median OS= 5.9 months); 2) docetaxel (ORR = 7%, median OS = 5.2 months) or 3) irinotecan (ORR = 0%, median OS= 4.0 months).

These numbers demonstrate the poor prognosis of this disease, and the unmet medical need for innovative therapeutic strategies.

Cancer Genome Atlas (TCGA) mapped a genomic landscape of gastric adenocarcinomas, and identified 4 sub-types:

• Tumor positive for Epstein-Barr virus (EBV) (8%), which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, ErbB2, PD-L1 and PD-L2;
• Microsatellite instable tumors (MSI-high) (22%), which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signaling proteins (PIK3CA, ErbB2, ErbB3, and EGFR);
• Genomically stable tumors (20%), which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins;
• Tumors with chromosomal instability (50%), which show marked aneuploidy and focal amplification of receptor tyrosine kinases and VEGFA.

Most of diffuse-type gastric adenocarcinomas were classified in genomically stable tumors. This subgroup of cancers, accounting for about 20 to 30% of gastric adenocarcinomas, is associated with particularly poor prognosis and resistance to chemotherapy. A proteomic landscape of diffuse-type gastric adenocarcinomas was recently reported.

Pembrolizumab, an anti-PDL1 drug granted with an accelerated approval by FDA in September 2017, exhibited promising activity in gastric adenocarcinoma patients previously treated with 1 or 2 lines of chemotherapy (ORR=11.6%, median PFS = 2.0 months, median OS= 5.6 months), especially in those with PDL1 positive tumors (ORR=22.7%). The tumor response was particularly high in patients with MSI-high tumor (ORR=57.1%). However the preliminary outcomes of the phase III KEYNOTE-061 trial (NCT02370498) recently released in the press suggest that pembrolizumab was not superior to paclitaxel in 592 patients with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line treatment with platinum and fluoropyrimidine doublet therapy (the hazard ratio (HR) for OS was 0.82 (95% confidence interval = 0.66-1.03; one sided P = .042) (http://www.ascopost.com/News/58377).

These outcomes suggest that, although being very promising, immunotherapy should be combined to other agents for being fully effective in gastric adenocarcinomas patients.

We propose a strategy based on molecular features to select the drugs that will be associated with atezolizumab, an anti-PDL1 drug, in patients with pre-treated advanced gastric adenocarcinomas:

• Patients with tumors positive for EBV or microsatellite instable tumors (30%) will be treated with atezolizumab and ipatasertib.
• Patients with genomically stable tumors (20%) will be treated with atezolizumab combined with bevacizumab.
• Patients with tumors with chromosomal instability (50%) will be treated with atezolizumab combined with bevacizumab.

Expected outcomes:

IMMUNOGAST trial will provide data about the clinical feasibility of biomolecular characterization of gastric adenocarcinomas for routine treatment adjustment. Moreover it should generate information about the relevance of adjusting combined immunotherapies based on molecular subtypes, in terms of clinical efficacy. Finally, translational research project outcomes should provide important data about relationships between efficacy and tumor immune gene spatial expression, along with tumor and circulating mutational burden. These outcomes may help identify the best candidates for tested combinations in the future.

Conditions

Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Adenocarcinoma; Advanced Gastric Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with tumors positive for EBV or microsatellite instable tumors (group 1)

Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).

Group Type: EXPERIMENTAL

Atezolizumab + Ipatasertib

Intervention Type: DRUG

Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.

Patients with genomically stable tumors (group 2)

Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).

Group Type: EXPERIMENTAL

Atezolizumab + Bevacizumab

Intervention Type: DRUG

Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.

Patients with tumors with chromosomal instability (group 3)

Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).

Group Type: EXPERIMENTAL

Atezolizumab + Bevacizumab

Intervention Type: DRUG

Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.

Interventions

Atezolizumab + Ipatasertib

Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.

Intervention Type: DRUG

Atezolizumab + Bevacizumab

Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically and/or cytologically documented recurrent advanced/metastatic gastric or gastroesophageal junction adenocarcinomas* previously treated with a platinum and fluoropyrimidine-based regimen.

• The gastric or gastroesophageal junction adenocarcinomas that overexpress HER2 should have previously been treated with trastuzumab, except in the case of contraindication.
• Patients older than 18 years
• Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Patients must have documented disease progression
• Patients who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Accessible tumor lesion (primitive lesion or metastasis) for trial dedicated tumor biopsy.
• Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (echo) or multigated acquisition (MUGA) scan within 28 days before day 1 of treatment.
• Child-Pugh class A
• Patients must have normal organ and marrow function:

• Absolute neutrophil count ≥ 1,500/μL, platelets ≥ 100,000/μL, hemoglobin ≥ 9 g/dL
• Total bilirubin ≤ 1.5 ULN except subject with documented Gilbert's syndrome, AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, Serum alkaline phosphatase ≤ 2.5 x ULN. Patients with bone metastases: alkaline phosphatase ≤ 5 x ULN.
• Albumin > 2.5 mg/dL.
• Glomerular filtration rate ≥ 60 mL/min as determined by the CKD-EPI equation (or reference methodology such as Iohexol or isotopic technic).
• Urine dipstick for proteinuria < 2+. If urine dipstick is ≥ 2+, 24-hour urine must demonstrate < 1 g of protein in 24 hours.
• Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).
• Female patients of childbearing potential must have a negative serum pregnancy test within 8 days of initiating protocol therapy.
• Female patients of childbearing potential must agree to use contraceptive methods with a low failure rate (< 1% per year) during the treatment period and for 6 months after the last dose of study drugs.
• Male patients of childbearing potential must agree to use contraceptive methods with a low failure rate during the treatment period and for 6 months after the last dose of study drugs.
• Patient is capable of understanding and complying with the protocol and has signed the informed consent document.
• Patients affiliated to a social insurance regime.

Exclusion Criteria

• Residual toxicity from previous treatment grade ≥1, except for alopecia or peripheral neuropathy grade ≤ 2
• Radiotherapy within 28 days before inclusion, except for palliative radiotherapy if patients recovered from all side effects
• Congenital risk of bleeding, or acquired coagulopathy, or curative anti-coagulant therapies (except for low molecular weight heparin).
• Active digestive bleeding within 3 months before inclusion
• Patients pretreated with one of the experimental drugs, other immune checkpoint inhibitor anti-cancer drugs (anti-PD1, anti-PDL1, anti-CTLA4, …), or with ramucirumab.
• Uncontrolled high cholesterol or triglyceride grade ≥ 2
• Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, congestive heart failure-New York Heart Association Class III or IV, active ischemic heart disease, myocardial infarction within the previous six months, uncontrolled diabetes mellitus, gastric or duodenal ulceration diagnosed within the previous 6 months, chronic liver or renal disease, or severe malnutrition.
• Current peripheral neuropathy of Grade ≥ 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0
• Active, second potentially life-threatening cancer
• Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS). Patient with a history of localized malignancy diagnosed over 5 years ago may be eligible provided he completed her adjuvant systemic therapy and remains free of recurrent or metastatic disease.
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

• Patients with vitiligo or alopecia
• Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• Any chronic skin condition that does not require systemic therapy
• Patients without active disease in the last 5 years may be included but only after consultation with the study physician
• Major surgery within 28 days before cycle 1, day 1
• Active infection requiring iv antibiotics at day 1 of cycle 1
• Medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. For example, patients with autoimmune disease that requires systemic steroids or immunosuppression agents should be excluded. Replacement therapy (eg., thyroxine, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest
• Patient is positive for the human immunodeficiency virus (HIV), HepBsAg, or HCV RNA.
• Live vaccine within 28 days of planned start of study therapy
• History of abdominal fistula, gastrointestinal perforation and/or intra-abdominal abscess within the previous 6 months
• History of Type I or Type II diabetes mellitus requiring insulin
• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese Hamster Ovary (CHO) cell proteins or loperamide drug or excipient
• Known hypersensitivity to any of the components of atezolizumab, bevacizumab or ipatasertib
• Participation in other interventional clinical research that may interfere with the experimental drugs efficacy
• History of severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Benoit YOU, MD

Role: PRINCIPAL_INVESTIGATOR

Service d'Oncologie Médicale - Centre Hospitalier Lyon Sud

Locations

Dijon - Centre Georges-Francois Leclerc

Dijon, , France

Site Status: NOT_YET_RECRUITING

Hcl - Hopital Edouard Herriot

Lyon, , France

Site Status: NOT_YET_RECRUITING

Aphm - Hopital La Timone

Marseille, , France

Site Status: NOT_YET_RECRUITING

Aphp - Hopital Saint-Louis

Paris, , France

Site Status: NOT_YET_RECRUITING

Aphp - Hopital Pitie Salpetriere

Paris, , France

Site Status: NOT_YET_RECRUITING

Bordeaux - Hopital Haut-Leveque

Pessac, , France

Site Status: NOT_YET_RECRUITING

Hcl - Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status: RECRUITING

Hcl - Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status: NOT_YET_RECRUITING

Toulouse - Iuct Rangueil-Larrey

Toulouse, , France

Site Status: NOT_YET_RECRUITING

Countries

France

Central Contacts

Benoit YOU, MD

Role: CONTACT

benoit.you@chu-lyon.fr

04 78 86 43 18 ext. +33

Sylvie BIN, MD

Role: CONTACT

sylvie.bin@chu-lyon.fr

04 72 11 53 66 ext. +33

Facility Contacts

François Ghiringhelli, MD

Role: primary

fghiringhelli@cgfl.fr

03 80 73 75 28 ext. +33

Julien Forestier, MD

Role: primary

julien.forestier@chu-lyon.fr

04 72 11 97 38 ext. +33

Laetitia Dahan, MD

Role: primary

laetitia.dahan@ap-hm.fr

04 91 38 60 23 ext. +33

Thomas Aparicio, MD

Role: primary

thomas.aparicio@aphp.fr

01 42 49 95 97, ext. +33

Jean-Baptiste Bachet, MD

Role: primary

jean-baptiste.bachet@aphp.fr

01 42 16 10 41 ext. +33

Denis Smith, MD

Role: primary

05 56 79 58 08 ext. +33

Benoit You, MD

Role: primary

benoit.you@chu-lyon.fr

04 78 86 43 18 ext. +33

Marion Chauvenet, MD

Role: primary

marion.chauvenet@chu-lyon.fr

0478861302 ext. +33

Nadim Fares, MD

Role: primary

fares.n@chu-toulouse.fr

05 61 32 21 42 ext. +33

Other Identifiers

2020-000297-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

69HCL19_0153

Identifier Type: -

Identifier Source: org_study_id